Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Closed 12-22 16:00:00 EST

26.02

-0.33

-1.25%

盘后26.02

+0.000.00%

16:10 EST

High26.99	Low25.92	Vol735.39K
Open26.20	D1 Closing26.35	Amplitude4.05%
Mkt Cap1.12B	Tradable Cap984.70M	Total Shares43.02M
T/O19.25M	T/O Rate1.94%	Tradable Shares37.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":26.02,"timestamp":1766437200000,"preClose":26.35,"halted":0,"volume":735393,"hourTrading":{"tag":"盘后","latestPrice":26.02,"preClose":26.02,"latestTime":"16:10 EST","volume":15620,"amount":406431.61,"timestamp":1766437803939},"delay":0,"floatShares":37844000,"shares":43021275,"eps":0.471309,"marketStatus":"Closed","change":-0.33,"latestTime":"12-22 16:00:00 EST","open":26.2,"high":26.99,"low":25.9225,"amount":19249127.769704,"amplitude":0.040512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.471309,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":26.35,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":26.35,"latestTime":"09:28 EST","volume":1617,"amount":42629.839329,"timestamp":1766413680032},"postHourTrading":{"tag":"盘后","latestPrice":26.02,"preClose":26.02,"latestTime":"16:10 EST","volume":15620,"amount":406431.61,"timestamp":1766437803939},"volumeRatio":0.564679,"impliedVol":0.5501,"impliedVolPercentile":0.516},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2592906349","title":"Pacira Biosciences Joins PROBE Consortium to Advance Osteoarthritis Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906349","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906349?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062821,"startTime":"0","endTime":"0","summary":"Pacira Biosciences Inc. has joined the PROBE  Consortium, a European Innovative Health Initiative -funded public-private partnership aimed at transforming osteoarthritis  research and patient care. The consortium brings together 38 partners from academia, industry, patient organizations, regulatory agencies, and health professionals to improve OA diagnosis and treatment by leveraging data from over 70 million individuals across multiple OA cohorts and real-world registries. Pacira will contribute valuable data, including findings from its ASCEND study on the investigational gene therapy PCRX-201, to support initiatives such as AI-driven disease progression prediction, development of new trial endpoints, and enhanced shared decision-making tools for patients and healthcare providers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL6LwH5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","BK4112","SG9999014039.USD","NDAQ","BK4588","LU2095319765.USD","PCRX","IE00B3QW5Z07.USD","BK4007","LU0314104364.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590529553","title":"Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590529553","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590529553?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:47","pubTimestamp":1765507663,"startTime":"0","endTime":"0","summary":"Shawn Cross, Chief Financial Officer of Pacira BioSciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL8Br7SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2590532394","title":"Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2590532394","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590532394?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:17","pubTimestamp":1765390664,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (PCRX) just shared new pilot study data on its ioveradeg cryoneurolysis system in chronic low back pain, alongside fresh FDA clearance for a Smart tip designed for deeper lumbar nerve access.\nSee our latest analysis for Pacira BioSciences.\nThat backdrop helps explain why the share price has climbed to around $24.77, with a strong year to date share price return but a weak five year total shareholder return. This suggests recent momentum is rebuilding after a tough few...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-valuation-check-after-new-iovera-cli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-valuation-check-after-new-iovera-cli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2590328595","title":"Pacira BioSciences Initiated at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328595","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590328595?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:14","pubTimestamp":1765296840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 11:14 ET (16:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2588985049","title":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2588985049","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588985049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:12","pubTimestamp":1764767540,"startTime":"0","endTime":"0","summary":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule Dec 3 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA2XRVTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2588046083","title":"Pacira Biosciences Grants Inducement Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046083?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766818,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc. has granted inducement awards to two new employees under its Amended and Restated 2014 Inducement Plan. The awards consist of restricted stock units for an aggregate of 2,200 shares of Pacira common stock. These units vest annually in four equal installments beginning on December 1, 2026, contingent on the employees' continued employment with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbPLcQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","PCRX","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD"],"gpt_icon":0},{"id":"2588046285","title":"Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA2XRVTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2588055845","title":"Pacira Biosciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With Iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055845?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:12","pubTimestamp":1764681131,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X802I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2588105340","title":"Pacira Biosciences Study Finds Iovera° Superior to Radiofrequency Ablation for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2588105340","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588105340?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680456,"startTime":"0","endTime":"0","summary":"Pacira BioSciences Inc. announced results from a 12-month randomized pilot study evaluating the safety and effectiveness of iovera° cryoneurolysis compared to radiofrequency ablation  for chronic low back pain. The study, which involved 30 patients and was published in the journal Pain Physician, reported that iovera° was associated with significant improvements in pain reduction and functional outcomes. Additionally, fewer patients treated with iovera° required additional spine injections after 180 days, and no treatment-related adverse events were observed. The results have already been published and presented in Pain Physician.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL86g9gw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4588","PCRX","LU2210150020.SGD","BK4007","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2586627260","title":"Pacira Biosciences: Seeks Injunction to Prevent Manufacture, Use, Sale of Generic Products Described in Each Co's Anda Filed With U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2586627260","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586627260?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:01","pubTimestamp":1764190879,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20OG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2586606172","title":"Pacira Biosciences Files Exparel® Patent Infringement Lawsuits Against the Whiteoak Group and Qilu Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2586606172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586606172?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:01","pubTimestamp":1764190879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2586260606","title":"Pacira Biosciences: Lawsuits Triggered 30-Month Stay of Final FDA Approval of Andas Under Hatch Waxman Act","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260606","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260606?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:01","pubTimestamp":1764190879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20OG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2586260623","title":"Pacira BioSciences Files Patent Infringement Lawsuits to Protect EXPAREL® Against Generic Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260623?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:01","pubTimestamp":1764190870,"startTime":"0","endTime":"0","summary":"Pacira BioSciences Inc. has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical  Co., Ltd. The lawsuit concerns alleged infringement related to EXPAREL . As a result, a 30-month stay of final FDA approval for the companies' Abbreviated New Drug Applications  has been triggered under the Hatch Waxman Act. EXPAREL is currently protected by 21 patents listed in the FDA's Orange Book, with expiration dates in 2041 and 2044. Pacira intends to vigorously defend its intellectual property rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL6HRTKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","PCRX","BK4585","IE00BKPKM429.USD","BK4007","NDAQ","BK4112","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2584634976","title":"Pacira Biosciences Chief Medical Officer Jonathan Slonin Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584634976","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584634976?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:32","pubTimestamp":1763587960,"startTime":"0","endTime":"0","summary":"Jonathan Slonin, Chief Medical Officer, reported a disposal of common shares of Pacira Biosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL7CDMpR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira Biosciences Chief Medical Officer Jonathan Slonin Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2584640201","title":"Pacira BioSciences Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584640201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584640201?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:00","pubTimestamp":1763380800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 07:00 ET (12:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2584421996","title":"Pacira Biosciences Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2584421996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584421996?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:11","pubTimestamp":1763377919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2583680933","title":"Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680933","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680933?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:00","pubTimestamp":1763161200,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 6 through Nov. 12, 2025. Source: VerityData. Pacira BioSciences  Doma Perpetual Capital Management raised its stake in the pain-management biopharmaceutical company to 2,936,794 shares. Doma did so through the purchase of 238,176 Pacira BioSciences shares from Sept. 10 through Oct. 7 at prices ranging from $23.77 to $26.50, on average. On Nov. 10, Doma issued an open letter to Pacira's board of directors, advocating for the company to hire bankers and conduct a formal sales process for the business. The letter cites \"management's unrelenting underperformance, out-of-control spending, and lack of prudent financial control.\". Following the latest sales, Cyrus Capital continues to own 7.3% of G","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTX","BK4106","BK4124","SION","BK4226","LU2065169927.USD","BTDR","ISBC","LU2065171402.SGD","USDT.USD.CC","PCRX","LU2065171311.SGD","USDT.USD.HKCC","BK4595","IE00B7SZL793.SGD","CNXC","LU2065170008.USD","BK4600","BK4139","IE00B19Z4B17.USD","IE0031619046.USD","BK4023","BK4007","IE00B66KJ199.SGD","BK4211"],"gpt_icon":1},{"id":"2583431514","title":"Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583431514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583431514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:13","pubTimestamp":1763068436,"startTime":"0","endTime":"0","summary":"Shawn Cross, Chief Financial Officer of Pacira Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLc1xHld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2582736977","title":"Pacira BioSciences to Join Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736977","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736977?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:00","pubTimestamp":1762866037,"startTime":"0","endTime":"0","summary":"Pacira Biosciences Inc. will participate in a fireside chat at the Jefferies London Healthcare Conference on November 18 at 1:30 PM GMT and at the 37th Annual Piper Sandler Healthcare Conference on December 2 at 1:30 PM ET. The company will discuss its commitment to delivering innovative, non-opioid pain therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on November 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL34Yd9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","PIPR","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","PCRX","BK4007","NDAQ","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","BK4127"],"gpt_icon":0},{"id":"2582387631","title":"BRIEF-Doma Perpetual Urges Pacira Biosciences To Immediately Explore Sale Of The Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387631","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582387631?lang=en_us&edition=fundamental","pubTime":"2025-11-11 09:12","pubTimestamp":1762823573,"startTime":"0","endTime":"0","summary":"BRIEF-Doma Perpetual Urges Pacira Biosciences To Immediately Explore Sale Of The BusinessNov 10 (Reuters) - DOMA PERPETUAL SENDS LETTER CALLING FOR THE BOARD OF DIRECTORS OF PACIRA BIOSCIENCES, INC. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUA9QSCYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":0.083},{"period":"3month","weight":-0.0116},{"period":"6month","weight":0.0875},{"period":"1year","weight":0.3464},{"period":"ytd","weight":0.3986}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.06786},{"month":2,"riseRate":0.642857,"avgChangeRate":0.021525},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.005065},{"month":4,"riseRate":0.6,"avgChangeRate":0.040098},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.043366}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction